



Medi-Cal Rx

Reminder: Provide Medical Justification for GLP-1 Drugs

April 1, 2026

What Pharmacy Providers and Prescribers Need to Know

As previously announced in the [Changes to Medi-Cal Rx, Effective January 1, 2026](#) alert, GLP-1 drugs are not covered by Medi-Cal Rx when used for weight loss or weight loss-related indications.

Medi-Cal Rx reviews and adjudicates prior authorizations (PAs) submitted for the following indications approved by the U.S. Food and Drug Administration (FDA) on a case-by-case basis to establish medical necessity and to determine if the member's individual needs are met:

- Wegovy® when used for cardiovascular disease
- Zepbound® when used for obstructive sleep apnea (OSA)

PA requests submitted for weight loss or weight loss-related indications will be reviewed for medical necessity for members younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit.

What Pharmacy Providers and Prescribers Need to Do

- Include the following information when submitting a PA request:
 - Diagnosis/diagnoses
 - Quantity/days' supply
 - Other products tried and the reason(s) why those products do not meet the member's needs
 - Contraindications and allergies
 - Chart notes/lab reports
 - Supporting literature, compendia, or treatment guidelines if for off label use
- Review the [Medi-Cal Rx Contract Drugs List](#) (CDL) for additional coverage options.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.